StreetInsider.com News Articles

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods C

Tue, 22 Sep 2026 08:14:11 -0400

PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Beta Bionics to integrate iLet system with Senseonics' Eversense 365 CGM

Tue, 22 Sep 2026 07:30:50 -0400

Beta Bionics, Inc. (Nasdaq: BBNX) announced an agreement to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics' Eversense 365 continuous glucose monitoring system, according to a company press release.

The commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026. Beta Bionics said it expects the iLet to support more continuous glucose monitoring manufacturer options than any other automated insulin delivery system upon that launch.

The two companies have also committed to integrating the mint system with Eversense 365 at a future date, though no timeline was provided.

"This collaboration

Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365

Tue, 22 Sep 2026 07:30:00 -0400

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system.

Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users.

The companies have also committed

Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365

Tue, 22 Sep 2026 07:30:00 -0400

The companies have also committed

Form 4/A Beta Bionics, Inc. For: Sep 09 Filed by: Hopman Mark

Fri, 18 Sep 2026 19:52:00 -0400

si-local-file:///var/storage/secattach/20260918/27081540.html

Beta Bionics Investors Who Lost Money: Contact Block & Leviton LLP About the Pending Securities Litigation

Fri, 18 Sep 2026 10:58:00 -0400

Boston, Massachusetts--(Newsfile Corp. - September 18, 2026) - Block & Leviton announces that a securities fraud lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) and certain of its executives. Investors who have lost money in their Beta Bionics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bbnx.

What is this all about?

According to the complaint, Beta Bionics and certain of its executives misled investors about the safety of the company's sole commercial product, the iLet Bionic Pancreas automated insulin pump. The complaint alleges that after receiving

Beta Bionics Investors Who Lost Money: Contact Block & Leviton LLP About the Pending Securities Litigation

Fri, 18 Sep 2026 10:58:00 -0400

What is this all about?

Form 4 Beta Bionics, Inc. For: Sep 16 Filed by: Hopman Mark

Thu, 17 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260917/27076032.html

Form 4 Beta Bionics, Inc. For: Sep 16 Filed by: Mensinger Mike

Thu, 17 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260917/27076034.html

Beta Bionics closes $172.5M public stock offering on Nasdaq

Thu, 17 Sep 2026 16:05:10 -0400

Beta Bionics, Inc. (Nasdaq: BBNX) announced the closing of an underwritten public offering of common stock, raising $172.5 million in gross proceeds before deducting underwriting discounts, commissions, and other offering expenses.

The offering comprised 7,652,175 shares of common stock priced at $17.25 per share, along with pre-funded warrants to purchase 1,043,484 shares at $17.2499 per share. The underwriters exercised their option in full, purchasing an additional 1,304,348 shares of common stock.

Beta Bionics stated it intends to use the net proceeds for general corporate purposes, which may include costs associated with the commercialization of its Mint product, expansion of manufacturing facilities, research

Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

Thu, 17 Sep 2026 16:05:00 -0400

IRVINE, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the closing of its previously announced underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. In addition, the underwriters exercised

Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock

Thu, 17 Sep 2026 16:05:00 -0400

Form 424B5 Beta Bionics, Inc.

Thu, 17 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260917/27072209.html

Form 8-K Beta Bionics, Inc. For: Sep 15

Thu, 17 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260917/27072210.html

Form 144 Beta Bionics, Inc. Filed by: Mensinger Mike

Wed, 16 Sep 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260916/27070829.html

Form 144 Beta Bionics, Inc. Filed by: Hopman Mark

Wed, 16 Sep 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260916/27070727.html

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law

Wed, 16 Sep 2026 09:17:15 -0400

PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):

Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Beta Bionics, Inc. (NASDAQ: BBNX); Erasca, Inc. (NASDAQ: ERAS); and Hub Group, Inc. (NASDAQ: HUBG): Grabar Law

Wed, 16 Sep 2026 09:17:15 -0400

PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) --

Aardvark Therapeutics, Inc. (NASDAQ: AARD):